

ACRUX FOUNDER BARRIE FINNIN RETIRES FROM THE BOARD

Acrux (ASX: ACR) today reported that Professor Barrie Finnin has retired from the board after twelve years' service as a non-executive director. Barrie was one of the founders of the Acrux business and is a co-inventor of the transdermal drug delivery technology upon which its products are based.

“Barrie has played an integral role in both developing Acrux’s core technology and its corporate growth over the last decade. Barrie has maintained a significant shareholding in the Company and has been a keen advocate of the Company among his colleagues in the pharmacy industry”, said Acrux Chairman Ross Dobinson. “We have enjoyed his professionalism and his intellect and wish him an enjoyable and well-earned retirement.”

The Board will appoint a suitably qualified non-executive director to replace Barrie in due course.

Contact

Ross Dobinson, Chairman: 03 9691 5920

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has two products marketed by licensees in the USA, one product approved in Europe, one product in registration in the USA and Europe and further products at earlier stages of development.
- Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.